Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : rVSV-SARS-CoV-2-S Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : NRx Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IIBR-100 (VSV-ΔG) is a self-propagating live virus vaccine that contains the spike protein of the Wuhan wild-type SARS-CoV-2 virus. Preclinical and phase 1/2 trials have demonstrated no safety signals of concern and have further demonstrated immunologic...
Product Name : IIBR-100
Product Type : Vaccine
Upfront Cash : Inapplicable
September 12, 2021
Lead Product(s) : rVSV-SARS-CoV-2-S Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : NRx Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Israel to Start COVID-19 Vaccine Human Trials on Nov. 1
Details : The Israel Institute for Biological Research began animal trials for its “BriLife” vaccine in March. The vaccine, the ministry said, has already tested well on a number of animal models & the IIBR has produced more than 25,000 doses for I & II phases...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 26, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Israel tests coronavirus vaccine prototype on rodents at defense lab
Details : A source familiar with IIBR activities told Reuters that trials were already under way on rodents. The source declined to identify the kind of rodent.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 31, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : rVaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Dyadic International, Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The research collaboration combines IIBR's renowned scientific capabilities and cGMP facilities with Dyadic's patented and proprietary C1 gene expression platform.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
February 25, 2020
Lead Product(s) : rVaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Dyadic International, Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : rVSV-SARS-CoV-2-S Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Israel Starts Human Trials on Covid-19 Vaccine as Schools Slowly Reopen
Details : The institute, which is overseen by the Defense Ministry, began animal trials for its “BriLife” vaccine in March and announced a week ago it had received regulatory approval to take it to the next stage.
Product Name : IIBR-100
Product Type : Vaccine
Upfront Cash : Inapplicable
January 11, 2020
Lead Product(s) : rVSV-SARS-CoV-2-S Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable